MEI Pharma (Nasdaq: MEIP) is a San Diego-based oncology drug development company with a pipeline of three clinical-stage drug candidates and a management team with proven oncology drug development experience. As of March 31, 2017, we had $56.8 million in cash, cash equivalents and short-term investments, with no outstanding debt. Our common stock is traded on the Nasdaq Capital Market under the symbol MEIP.